Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH
Shuttle Pharmaceuticals — Investor Presentation (January 2024)
12 slides from Shuttle Pharmaceuticals's investor presentation, January 2024
Slide 1: Shuttle Pharmaceuticals, Inc. Investor Presentation
Shuttle Pharmaceuticals, Inc. Nasdaq: SHPH Investor Presentation January 2024
Slide 2: Disclaimers
Disclaimers Forward Looking Statements All of the information contained within this business plan presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle” o
Slide 3: The Fundamental Problem Facing Radiation Therapy
The Fundamental Problem Facing Radiation Therapy Cancers are resistant to cure by radiation therapy because tumors are surrounded by radiation sensitive normal tissues that limit the maximum treatment dose Strategies to overcome cancer resistance to radiation therapy: Sensitize Cancer Cells To Rad
Slide 4: Clinical Pipeline
Clinical Pipeline Pipeline composed of two parts: Ropidoxuridine, our lead clinical drug candidate, which sensitizes rapidly growing cancer cells and, various selective HDAC (histone deacetylase) inhibitors – which sensitize cancer cells and stimulate the immune system. 4 Shuttle Pharmaceuticals Hol
Slide 5: Ropidoxuridine Platform: Clinical Studies
Ropidoxuridine Platform: Clinical Studies Ropidoxuridine (IPdR) is the prodrug of IUdR IUdR is a powerful radiation sensitizer showing Phase II efficacy in NIH sponsored clinical trials IUdR and RT for sarcoma patients resulted in improved survival IUdR and RT for glioblastoma and anaplastic
Slide 6: Ropidoxuridine Platform: Recent Activities
Ropidoxuridine Platform: Recent Activities Results of Pre-IND Meeting with the FDA – IND approved, safe to proceed letter received January 5, 2024 Received written responses to questions submitted for a Type B pre-Investigational New Drug Application (PIND) meeting with the U.S. Food and Drug Ad
Slide 7: HDAC Inhibitor Platform: Overview
HDAC Inhibitor Platform: Overview Shuttle Pharma has discovered novel HDAC inhibitors using proprietary technology. Cancer radiation sensitization, normal tissue protection and selective HDAC6 inhibition are observed in preclinical model testing. Our HDAC inhibitors are undergoing pre-clinical e
Slide 8: Intellectual Property Portfolio for Radiation Sensitizers
Intellectual Property Portfolio for Radiation Sensitizers Intellectual property for Ropidoxuridine includes novel formulations demonstrating improved drug bioavailability (in a preclinical animal model) and for sensitizing cancers to radiation therapies. Our HDAC inhibitor intellectual property
Slide 9: Clinical Development Strategy for Radiation Sensitizers
Clinical Development Strategy for Radiation Sensitizers Shuttle Pharma has a broad pipeline to improve clinical outcomes of patients treated with radiation therapy for cancer Priority #1: Advance Ropidoxuridine & RT to treat brain tumors (glioblastoma) Capitalize on Ropidoxuridine as an orally
Slide 10: Financial Overview
Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table as of September 30, 2023 Common Stock 15,999,125 Exchange/Ticker NASDAQ: SHPH Fully Vested Restricted Stock Units (RSUs) 90,549 Closing Stock Price* $0.51 RSUs Outstanding 168,050 52 Wk High/Low* $3.42 - $0.42 Warrants Outst
Slide 11: Shuttle's Experienced Leadership Team
Shuttle’s Experienced Leadership Team Founder & CEO of Shuttle Served as President Served as CFO of Pharma since 2012. Chairman, & COO of Shuttle Shuttle Pharma since Board of Directors 2017 Pharma since 2012 2019 Member, Board of Directors, MBA George MHSA George Neopharm Inc. 1990 Wash
Slide 12: Thank You
THANK YOU Anatoly Dritschilo, MD CEO, Shuttle Pharmaceuticals Holdings, Inc. Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org 12
Shuttle Pharmaceuticals Holdings — Investor Presentation (January 2024) on 6ix